At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 60 enrolled
Drug / intervention
Memantine +1 moredrug
Likely dose
Memantine 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
In Brief
A Phase 4 clinical trial evaluating Memantine and Placebo for Alzheimer's Disease. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The purpose of the study is to determine whether memantine delays the progression of driving impairment in patients with mild Alzheimer's Disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
CollaboratorsForest Laboratories
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2007
Enrollment StartJul 2007
Primary CompletionOct 2012
TodayJul 2026
First PostedMay 21, 2007
Enrollment StartJul 1, 2007
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 19.1 years ago
Interventions
Memantinedrug
One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
Placebodrug
One tablet placebo morning and evening (BID) for 12 months